Core Insights - A strategic agreement between Abu Dhabi Health Data Services (ADHDS) and TELUS Health aims to introduce personalized employee wellbeing solutions in the UAE, integrating wellness, precision medicine, and AI-driven healthcare innovation [1][2] - The Employee Assistance Program (EAP) will feature over 40 modules focused on emotional, lifestyle, and wellbeing support, delivered in local languages to enhance user experience [1][2] - The collaboration seeks to create a health and wellbeing environment that improves workplace focus, reduces absenteeism, and enhances productivity and engagement for employers [2] Company Overview - M42, headquartered in Abu Dhabi, is a global health champion leveraging AI, technology, and genomics to innovate healthcare solutions [3] - Established in 2023, M42 operates over 480 facilities across 26 countries and employs more than 20,000 individuals, including partnerships with renowned healthcare providers [4] - ADHDS, a key asset of M42, was founded in 2018 as a Public-Private Partnership to operate Malaffi, the Abu Dhabi Health Information Exchange, and has been recognized for its rapid deployment of advanced digital healthcare solutions [7] Industry Context - The UAE is experiencing a significant shift in organizational approaches to employee wellbeing, with a focus on integrating mental health support and wellness solutions [2] - The partnership between ADHDS and TELUS Health aims to enhance healthcare delivery through AI innovation and digital infrastructure, ultimately building more resilient health systems [2][6] - TELUS Health operates in over 200 countries, supporting more than 160 million individuals in their physical, mental, and financial wellbeing journeys [8][9]

Core Viewpoint - vTv Therapeutics Inc. has announced a Phase 2 clinical study for cadisegliatin, an oral adjunctive therapy to insulin for type 2 diabetes, in collaboration with M42's Insights Research Organization & Solutions [1][2] Group 1: Clinical Study Details - The Phase 2 study protocol has been submitted to the Department of Health Abu Dhabi and aims to evaluate the safety and efficacy of cadisegliatin over a 12-month period [1] - The trial will enroll approximately 300 patients with type 2 diabetes who are treated with insulin, randomized into three groups: two cadisegliatin dose groups (400 mg and 800 mg once daily) and a placebo control group [1] - The trial will take place in the UAE, Jordan, and Tunisia, with the first patient visit expected in Q1 2026 [1] Group 2: Company and Product Information - Cadisegliatin (TTP399) is a novel oral small molecule being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes and has received Breakthrough Therapy designation from the FDA [4][6] - vTv Therapeutics is focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases, with cadisegliatin leading its clinical pipeline [6] Group 3: Collaboration and Market Potential - The collaboration with M42 allows vTv to expand the geographic footprint for cadisegliatin, targeting populations with high prevalence of type 2 diabetes, particularly in the UAE [2][3] - IROS, as the funding partner for the study, aims to leverage its expertise in clinical research to potentially impact the lives of millions with type 2 diabetes [3][7]

Core Insights - NeOnc Technologies Holdings, Inc. is expanding its operations into the Middle East through strategic partnerships and governance enhancements [1][2][3] Group 1: Strategic Developments - NeOnc's subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), enhancing its clinical development capabilities [1][3] - The partnership with IROS, part of the M42 group, provides access to a world-class health ecosystem, facilitating accelerated clinical trials for NeOnc's cancer therapies [3][5] - NuroMENA is expanding its Board of Directors to include key partners from Quazar Investment, aiming to strengthen regional governance and growth [2][4] Group 2: Leadership and Governance - The new board members include Waleed K. Al Ali, CEO of Quazar Investment, enhancing the leadership team overseeing NuroMENA's regional strategy [4] - The board will work alongside existing directors to establish a strong foundation for operational excellence and strategic leadership in the Middle East [5] Group 3: Clinical and Research Capabilities - IROS is recognized for its commitment to advancing clinical research and real-world evidence, leveraging cutting-edge technologies to drive innovation [6][7] - The partnership with IROS is expected to enable NeOnc to conduct clinical trials with exceptional speed, quality, and integrity, positioning Abu Dhabi as a global hub for oncology innovation [5][6] Group 4: Company Background - NeOnc Technologies is focused on developing therapies for central nervous system cancers, with its NEO™ drug development platform producing novel drug candidates [11] - The company’s therapeutics, NEO100™ and NEO212™, are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [11]

Core Insights - Serina Therapeutics congratulates its strategic partner Juvenescence Ltd. for securing $150 million in Series B financing led by M42, which will enhance their drug development capabilities [1][2][3] - The partnership aims to establish a drug development hub in Abu Dhabi, integrating AI-enabled drug discovery with advanced clinical infrastructure to expedite the creation of innovative therapies targeting age-related diseases [2][3] - Juvenescence's leadership has a proven track record in biopharma, having previously led significant deals and developed medicines with peak annual sales totaling $30 billion [7][8] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications, utilizing its proprietary POZ Platform to enhance the efficacy and safety of various therapeutic modalities [4] - Juvenescence is an AI-enabled biotech company dedicated to extending healthy lifespan by targeting core aging mechanisms to treat age-related diseases [6][8] - M42, a global health company, combines AI, technology, and genomics to innovate healthcare solutions, operating over 480 facilities across 26 countries [9][11]